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Conclusions: In the majority of patients with progressive 
CRPC and a symptomatic pelvic tumor, PPRT with 30-39 Gy 
contributes to relief of macroscopic hematuria, pain and 
other pelvic symptoms as well as improved QOL, with little 
toxicity. Future studies should investigate whether PPRT 
regimens can be further simplified.  
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Purpose/Objective: The therapeutic ratio of antalgic 
radiotherapy for bone metastases might be improved by 
decreasing the radiotherapy dose to the normal tissue and/or 
by increasing the dose to the bone metastases. A three arm 
randomized phase II trial comparing single fraction 
conventional radiotherapy with 2 different dose levels of 
single fraction Biological Image Guided Stereotactic 
RadioSurgery (BIG-SRS) will allow us to select the treatment 
arm with sufficient promise of efficacy to justify its 
evaluation in a definitive phase III trial. 
Materials and Methods: Patients with painful bone 
metastases without major neurological symptoms were 
enrolled. All patients underwent a 18[F]-FDG-PET-CT prior to 
irradiation. Patients were randomized (1:1:1) to receive 
either 8 Gy in a single fraction with conventional 
radiotherapy (arm A) or 8 Gy in a single fraction with dose-
painting-by-numbers (DPBN) (dose range between 6 and 10 
Gy) (arm B) or 16 Gy in a single fraction with DPBN (dose 
range between 14 and 18 Gy) (arm C). The primary endpoint 
was overall pain response at 1 month, defined as the sum of 
complete and partial pain responses to treatment assessed 
using a visual analogue scale (range 0-10). Analysis was done 
by intention to treat and pairwise tests are based on a score 
statistic and Fisher's information pairs. The arm with the 
highest score statistic is selected as the most promising to 
continue in phase III. 
Results: 
 
Forty-five patients were randomized to a treatment group. 
Eight patients (53%), 12 patients (80%) and 9 patients (60%) 
had an overall response to treatment in arm A, B and C, 
respectively. The estimated odds ratio of arm A vs B is 3.5 
(95% CI: 0.44-17.71) with a score statistic of 2.4 (p = 0.12). 
Patients in Arm B showed a significant improvement in QOL 
score at 1 month compared with Arm A (pain characteristic, 
insomnia and appetite loss, p<0.05). The estimated odds 
ratio of arm A vs C is 1.31 (95% CI: 0.31-5.58) with a score 
statistic of 0.14 (p = 0.71). No differences in QOL between 
Arm A and C were observed. 
Conclusions: A single fraction of 8 Gy by means of BIG-SRS 
shows a promising overall pain response of 80%, meriting 
further evaluation in phase III.  
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